Systematic and Targeted Prostate Biopsy: a Five-Year Experience in a High-Volume Center
Prostate biopsy is the gold standard diagnostic tool for prostate cancer. The number of targeted prostate biopsies based on multiparametric resonance imaging have increased in recent years, and this method is becoming increasingly utilized in patients in repeat biopsy settings, but also for biops...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2024-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/466905 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Prostate biopsy is the gold standard diagnostic tool for prostate cancer. The number
of targeted prostate biopsies based on multiparametric resonance imaging have increased in recent
years, and this method is becoming increasingly utilized in patients in repeat biopsy settings, but also
for biopsy-naive patients. The aim of this study was to analyze and present our results for the purpose
of self-control and education. In the time period between January 2018 and December 2022, there
were a total of 3385 prostate biopsies performed at the University Hospital Centre Zagreb. There were
2636 systematic (12 core) and 749 cognitive targeted biopsies, with an increasing trend in favor of
targeted biopsy. The positivity of systematic biopsy was 45%, whereas positivity for targeted biopsies
was 53.3%. The positivity of PI-RADS 3 lesions for targeted biopsies was 35%, 61% for PI-RADS
4, and 86% for PI-RADS 5. The median number of positive systematic cores was 3, and 4 cores for
targeted biopsies, while the median cancer core involvements were 30% for systematic and 60% for
targeted cores. In targeted cores, there was a higher percentage of ISUP grade 2 and 3 cancers when
compared with systematic cores. Targeted biopsy is a valuable addition to the standard systematic
biopsy in patients with suspicious lesions described on mpMRI. |
|---|---|
| ISSN: | 0353-9466 1333-9451 |